全文获取类型
收费全文 | 20498篇 |
免费 | 1129篇 |
国内免费 | 412篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 1142篇 |
妇产科学 | 1313篇 |
基础医学 | 2233篇 |
口腔科学 | 155篇 |
临床医学 | 1452篇 |
内科学 | 3113篇 |
皮肤病学 | 206篇 |
神经病学 | 2247篇 |
特种医学 | 266篇 |
外国民族医学 | 3篇 |
外科学 | 2295篇 |
综合类 | 2591篇 |
现状与发展 | 4篇 |
预防医学 | 1166篇 |
眼科学 | 66篇 |
药学 | 2100篇 |
12篇 | |
中国医学 | 725篇 |
肿瘤学 | 874篇 |
出版年
2023年 | 169篇 |
2022年 | 398篇 |
2021年 | 589篇 |
2020年 | 500篇 |
2019年 | 474篇 |
2018年 | 496篇 |
2017年 | 564篇 |
2016年 | 546篇 |
2015年 | 525篇 |
2014年 | 945篇 |
2013年 | 1273篇 |
2012年 | 874篇 |
2011年 | 1072篇 |
2010年 | 909篇 |
2009年 | 835篇 |
2008年 | 913篇 |
2007年 | 898篇 |
2006年 | 919篇 |
2005年 | 801篇 |
2004年 | 670篇 |
2003年 | 656篇 |
2002年 | 570篇 |
2001年 | 509篇 |
2000年 | 485篇 |
1999年 | 386篇 |
1998年 | 323篇 |
1997年 | 353篇 |
1996年 | 355篇 |
1995年 | 304篇 |
1994年 | 313篇 |
1993年 | 269篇 |
1992年 | 288篇 |
1991年 | 270篇 |
1990年 | 297篇 |
1989年 | 229篇 |
1988年 | 179篇 |
1987年 | 158篇 |
1986年 | 179篇 |
1985年 | 239篇 |
1984年 | 211篇 |
1983年 | 137篇 |
1982年 | 178篇 |
1981年 | 141篇 |
1980年 | 120篇 |
1979年 | 108篇 |
1978年 | 96篇 |
1977年 | 78篇 |
1976年 | 59篇 |
1975年 | 44篇 |
1974年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
目的:探讨甲状旁腺激素(PTH)对大鼠牵张成骨(DO)过程中ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因表达的影响。方法30只雄性大鼠制备大鼠下颌骨DO模型。随机分5组,每组6只。第1组(只有牵张无PTH),术后8周取材,应用HE染色及微CT检测,以确定成骨情况。第2组(有牵张无PTH),第3组(有牵张有PTH),第4组(无牵张有PTH),第5组(对照组:无牵张无PTH)。2、3、4组及对照组术后1周取材,RT-PCR测定ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因的表达。结果第1组,新骨形成,骨质充满牵张区,骨质连续,大鼠建模成功。RT-PCR检测结果显示,2、3、4组与对照组比较,OPN、COL1、RUNX2、ALP基因表达有明显提高(P<0.05),其中第3组最为明显。ONC、C-FOS、VEGF基因2、3、4组与对照组比较差异无统计学意义(P>0.05)。结论 PTH在 DO 过程中,间歇性给以 PTH的作用只有在牵张期发挥作用,其对 OPN、COL1、RUNX2、ALP基因表达能够获得理想的协同作用。 相似文献
2.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
3.
目的 观察高转换型肾性骨病中骨保护素及其配体 (OPG,RANKL)的表达,并与骨形态计量学指标进行相关分析。 方法 选择10例慢性肾衰尿毒症患者和3例正常人进行髂骨活检术,获得骨组织标本。采用免疫组化方法检测OPG和RANKL蛋白质的表达。采用全自动图像分析系统进行骨组织形态计量学测定。结果 10例慢性肾衰尿毒症患者经骨病理学检查证实均为高转换型骨病,以破骨细胞活化形成骨吸收陷窝伴或不伴骨矿化不全为特点。免疫组化显示尿毒症患者骨组织中以RANKL阳性表达为主。与正常对照相比,RANKL阳性表达细胞数目显著增加,OPG阳性表达细胞数目显著减少。尿毒症患者RANKL的阳性表达细胞数目与骨吸收面积和破骨细胞数目呈显著正相关。结论 高转换型肾性骨病中,PTH的溶骨作用可能是通过OPG/RANKL/RANK系统介导的。 相似文献
4.
5.
6.
Acute Immobilization Stress and Intraventricular Injection of CRF Suppress Naloxone-Induced LH Release in Ovariectomized Estrogen-Primed Rats 总被引:1,自引:0,他引:1
Tatsuo Akema Atsuhiko Chiba Reiji Shinozaki Morihiro Oshida Fukuko Kimura & Jun-ichi Toyoda 《Journal of neuroendocrinology》1996,8(8):647-652
The present study was undertaken to evaluate the role and possible interaction of the endogenous opioid peptide (EOP) and corticotropin-releasing factor (CRF) in the acute stress-induced suppression of gonadotropin secretion in ovariectomized estrogen-primed rats. An intravenous (i.v.) injection of naloxone (10 or 20 mg/kg), an EOP antagonist, significantly elevated serum luteinizing hormone (LH) levels within 10 min in non-stressed animals. The naloxone-induced LH release was completely eliminated when tested 30 min after the onset of acute immobilization. In a subsequent study, it was found that suppression of the naloxone-induced LH release occurred as early as 5 min after the stress onset, and was still evident 60 min after the end of a 30-min period of immobilization. The effect of naloxone was restored 3 h after liberation of the animal from the 30-min immobilization. An intraventricular (i.c.v.) injection of CRF (1 or 5 μg) also significantly suppressed, in a dose-related manner, the effect of a subsequent i.v. injection of naloxone. However, an i.c.v. injection of α -helical CRF(9-41) (25 or 50 μg), a CRF antagonist, prior to immobilization, could not interfere with the suppressive effect of stress on naloxone-induced LH release. These results suggest that both acute immobilization stress and CRF can inhibit the LH secretory activity without mediation by EOP neurons. However, the stress-related suppression may involve non-CRF mechanism(s). 相似文献
7.
PTH has diverse effects on bone metabolism: anabolic when given intermittently, catabolic when given continuously. The cellular
mechanisms underlying the varying target cell response are not clear yet. PTH induces RGS-2, a member of the Regulator of
G-protein Signaling protein family, via cAMP/PKA, and inactivates PKC-mediated signaling. To investigate intracellular signaling
pathways with different PTH concentration-time patterns, we treated UMR 106-01 osteoblast-like cells in a perfusion system.
PTH was administered intermittently (4 min/h, 10−7 M) or continuously at an equivalent cumulative dose (6.6 × 10−9 M). cAMP was measured using radioimmunoassay, mRNA levels using real-time rtPCR and ribonuclease protection assay, and protein
levels using Western immunoblotting. A single PTH pulse transiently increased cAMP levels by 2000% ± 1200%. In contrast to
continuous PTH exposure, cAMP induction remained unchanged with intermittent PTH, ruling out desensitization of the PTH receptor.
In continuously perfused cells, RGS-2 abundance was three to five times higher than in cells intermittently exposed to PTH
for up to 12 h. MKP-1 and -3 were significantly less induced with pulsatile PTH; exposure-mode-dependent differences in MMP-13
and IGFBP-5 were small. Pulsatile but not continuous PTH administration prevents PTHrP receptor desensitization and accumulation
of RGS-2 in osteoblasts, which should preserve PKC-dependent signaling. 相似文献
8.
S. Tsagarakis Feng Ge L. H. Rees G. M. Besser A. Grossman 《Journal of neuroendocrinology》1989,1(2):129-133
While extensive evidence suggests that adrenoceptors play an important role in the control of growth hormone in the rat, there are few studies involving the direct measurement of growth hormone-releasing hormone (GHRH). We have therefore developed a radioimmunoassay for rat GHRH, and used it to investigate the modulation of GHRH release by noradrenaline from incubated rat hypothalamus in vitro. The GHRH radioimmunoassay had no significant cross-reactivity with other hypothalamic or GHRH-related peptides, and was sensitive to 4 pg/tube; intra- and interassay coefficients of variation were 6% and 12% respectively. Single incubated rat hypothalami produced a stable and readily measurable output of GHRH in successive 20 min incubations after an initial 60 min preincubation; the release of GHRH was increased in the presence of 56 mM KCI, but did not respond to KCI-depolarization when calcium was excluded from the medium. Stimulated GHRH release was identical to synthetic rat GHRH(1–43) on high-performance liquid chromatography and Sephadex G-75 chromatography.
Noradrenaline stimulated GHRH secretion in a dose-dependent manner in the concentration range 10−10 — 10−6 M, with a plateau in response at 10−7 M. Stimulation with noradrenaline 10−7 M was blocked by idazoxan 10−5 M and attenuated by thymoxamine 10−5 M, but was unaffected by timolol 10−5 M. Both the α2 -adrenoceptor agonist guanfacine, and the α1 -adrenoceptor agonist methoxamine, specifically stimulated GHRH secretion.
It is concluded that noradrenaline stimulates the release of GHRH at both α1 and α2 -adrenoceptors. 相似文献
Noradrenaline stimulated GHRH secretion in a dose-dependent manner in the concentration range 10
It is concluded that noradrenaline stimulates the release of GHRH at both α
9.
10.
Anna Spada†‡ Farzin Reza-Elahi†‡ rea Lania†‡ Atanasio Pandiella†† Monique Bassetti†† Nicoletta Bazzoni† Paloma Gil de Alamo† Giovanni Faglia† 《Journal of neuroendocrinology》1991,3(1):51-56
The effect of thyrotrophin-releasing hormone (TRH) on intracellular free Ca2+ concentration, [Ca2+)i, was investigated with the fluorescent dye fura-2 in cell suspensions obtained from 13 human growth hormone-secreting adenomas and 6 adrenocorticotrophin-secreting adenomas. Preoperatively, 9 out of 13 acromegalic patients showed a positive growth hormone response to TRH administration while none of the 6 patients with Cushing's disease had a plasma adrenocorticotrophin increase after TRH injection. In all the growth hormone-secreting adenomas the addition of TRH (100 nM) caused a significant rise in [Ca2+]i (from a resting level of 133±40 (±SD) to a value of 284±119 nM at 100 nM TRH, n = 42; P<0.001). The transient induced by TRH was found to have a dual origin, one due to Ca2+ mobilization from intracellular stores which was maintained in presence of EGTA (3mM) and verapamil (10 μM) and a plateau phase due to Ca2+ influx from the extracellular media. Somatostatin (0.1 μM) lowered both resting [Ca2+]i and TRH-induced transients. The effect of gonadotrophin-releasing hormone on [Ca2+]i was evaluated on cell suspensions obtained from 6 growth hormone-secreting adenomas. Gonadotrophin-releasing hormone (100 nM) caused a marked rise in [Ca2+]i (from 179±25 to 283±15nM) on the cell suspension obtained from the only in vivo responsive adenoma while it was ineffective in the remaining 5. Although TRH was ineffective in modifying plasma adrenocorticotrophin levels in all patients with Cushing's disease, in 5 out of 6 tumors the addition of 100 nM TRH caused a significant rise in [Ca2+]i (from 102.5 ± 36 to 163±66 nM, n = 22; P < 0.005). However, the effect of TRH on [Ca2+]i was significantly lower than that caused by arginine vasopressin, a physiological stimulator of adrenocorticotrophin release ([Ca2+]i values; 145±78 nM at 100 nM TRH versus 300±140 at 10 nM arginine vasopressin, n = 15; P<0.05). Moreover, the effect of arginine vasopressin on [Ca2+]i was detectable at concentrations as low as 0.1 nM while TRH was effective at concentrations higher than 1 nM. By contrast, gonadotrophin-releasing hormone was ineffective in increasing [Ca2]i in all the adrenocorticotrophin-secreting adenomas studied. Collectively, these data indicate that sensitivity to TRH is present in almost all the growth hormone- and adrenocorticotrophin-secreting adenomas independently of the responsiveness of the individual patients to the peptide. 相似文献